-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23

Benzinga·10/13/2026 20:50:23
Listen to the news
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.